Uncommon Cancers of the Prostate

Textbook of Uncommon Cancer, Third Edition

Volumn , Issue , 2006, Pages 38-65

  Tagawa, Scott T ^a,b   Hamid, Omid ^b   Skinner, Eila ^b   Kumar, Parvesh ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Lymphoma; Prostate cancer; Sarcoma; Small cell carcinoma; Transitional cell carcinoma

Indexed keywords

EID: 84876090792     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470030542.ch4     Document Type: Chapter

References (333)

1. Partin AW, Rodriguez R. The molecular biology, endocrinology, and physiology of the prostate and seminal vesicles. In Walsh PC (ed-in-chief), Retik AB, et al. (eds) Campbell's Urology, 8th ed. Philadelphia, Pennsylvania: Saunders, 2002: 1237-1296.
2. Scher HI, et al. Cancer of the prostate. In Devita VT Jr, Hellman S, Rosenberg SA (eds) Cancer Principles and Practice of Oncology, 7th ed. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins, 2005: 1192-1259.
3. Jemal A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
4. Mostofi FK, Price EB Jr. Atlas of Tumor Pathology:Tumors of the Male Genital System. Second Series. Fascicle 8. Washington, District of Columbia: Armed Forces Institute of Pathology, 1973: 177-259.
5. Sommers S.C. Endocrine changes with prostatic carcinoma. Cancer 1957; 10: 345-58.
6. Pretl K. Zur Frage der Endokrinie der menschlichen Vorsfeherdruse. Virchows Arch A Pathol Anat 1944; 312: 392-404.
7. Feyrter F. Uber das urogenitale Helle-Zelien System des Menschen. Z Mikrosk Anat Forsch 1951; 57: 324-44.
8. diSant'Agnese PA, et al. Human prostatic endocrine-paracrine (APUD) cells. Arch Pathol Lab Med 1985; 109: 607-12.
9. Bonikos DS, Bensch K.G. Endocrine cells of bronchial and bronchiolar epithelium. Am J Med 1977; 63: 765-71.
10. Azzopardi JG, Evans D.J. Argentaffin cells in carcinoma: differentiation from lipofuscin and melanin in prostatic epithelium. J Pathol 1971; 104: 247-51.
11. Berger CL, Goodwin G, Mendelsohn G, et al. Endocrine related biochemistry in the spectrum of human lung carcinoma. J Clin Endocrinol Metab 1981; 53: 422-9.
12. Schron DS, Gipson T, Mendelsohn G. The histogenesis of small cell carcinoma of the prostate. An immunohistochemical study. Cancer 1984; 53: 2478-80.
13. Spieth ME, Lin G, Nguyen T.T. Diagnosis and treating small-cell carcinomas of prostatic origin. Clin Nucl Med 2002; 27: 11-7.
14. Wenk RE, et al. Ectopic ACTH, prostatic oat cell carcinoma and marked hypernatremia. Cancer 1977; 40: 773-8.
15. Ro JY, et al. Small cell carcinoma of the prostate. II. Immunohistochemical and electron microscopic studies of 18 cases. Cancer 1987; 59: 977-82.
16. Wise HM Jr, et al. Hyperadrenocorticism associated with 'reactivated' prostatic carcinoma. Surgery 1965; 57: 655-64.
17. Hall T.C. Symptomatic hypokalaemic alkalosis in hyperadrenocorticism secondary to carcinoma of the prostate. Cancer 1968; 21: 190-2.
18. Newmark SR, Dlhuh RG, Bennett A.H. Ectopic adrenocorticotropin syndrome with prostatic carcinoma. Urology 1973; 2: 666-8.
19. Lovern WJ, et al. Ectopic ACTH production in disseminated prostatic adenocarcinoma. Urology 1975; 5: 817-20.
20. Holland E.A. Prostatic adenocarcinoma with ectopic ACTH production. Br J Urol 1978; 50: 538-41.
21. Hindson DA, Knight LL, Ocker J.M. Small-cell carcinoma of prostate. Transient complete remission with chemotherapy. Urology 1985; 26: 182-4.
22. Ghandur-Mnaymneh L, Satterfield S, Block N.L. Small cell carcinoma of the prostate gland with inappropriate antidiuretic hormone secretion: morphological, immunohistochemical and clinical expressions. J Urol 1986; 135: 1263-6.
23. Bleichner JC, Chun B, Klappenbach R.S. Pure small cell carcinoma of the prostate with fatal liver metastasis. Arch Pathol Lab Med 1986; 110: 1041-4.
24. Van Haaften-Day C, et al. Xenografted small cell undifferentiated cancer of prostate: possible common origin with prostatic adenocarcinoma. Prostate 1988; 11: 271-9.
25. Tetu B, et al. Small cell carcinoma of the prostate, Part 1: A clinicopathologic study of 20 cases. Cancer 1987; 59: 1803-9.
26. Capella C, et al. The endocrine component of prostatic carcinomas, mixed adenocarcinoma-carcinoid tumors, and non-tumor prostate: histochemical and ultrastructural identification of the endocrine cells. Histopathology 1981; 5: 175-92.
27. Bono AV, Pozzi E. Endocrine-paracrine cells in prostatic carcinoma and clinical course of the disease. Eur Urol 1985; 11: 185-8.
28. Smedley HM, Brown C, Turner J. Ectopic ACTH-producing lung cancer presenting with prostatic metastases. Postgrad Med J 1983; 59: 371-2.
29. Hodge GB, Carson C.C. Oat cell carcinoma of lung masquerading as prostatic carcinoma. Urology 1985; 25: 69-70.
30. Barkin J, et al. Hypercalcemia associated with cancer of prostate without bony metastases. Urology 1984; 24: 368-71.
31. Pruneri G, et al. Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: neuroendocrine expression in patients untreated and treated with androgen deprivation therapy. Prostate 1998; 34: 113-20.
32. Vuitch MF, Mendelsohn G. Relationship of ectopic ACTH production to tumor differentiation. A morphologic and immunohistochemical study of prostatic carcinoma with Cushing's syndrome. Cancer 1982; 47: 296-9.
33. Slater D. Carcinoid tumour of the prostate associated with inappropriate ACTH secretion. Br J Urol 1985; 57: 591-2.
34. Sellwood RA, et al. Inappropriate secretion of antidiuretic hormone by carcinoma of the prostate. Br J Surg 1969; 56: 933-5.
35. Carey RM, et al. Ectopic secretion of corticotropin-releasing factor as a cause of Cushing's syndrome. A clinical, morphologic and biochemical study. N Engl J Med 1984; 311: 13-20.
36. Jelbart ME, et al. Ectopic hormone production by a prostatic small cell carcinoma xenograft line. Mol Cell Endocrinol 1988; 55: 167-72.
37. Reeve JG, et al. Neuron specific enolase expression in carcinoma of the lung. Br J Cancer 1986; 53: 519-28.
38. Ellis DW, et al. Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate. Am J Clin Pathol 1984; 81: 279-84.
39. Heyderman E, Brown BM, Richardson T.C. Epithelial markers in prostatic, bladder and colorectal cancer. An immunoperoxidase study of epithelial membrane antigen, carcino-embryonic antigen, and prostatic acid phosphatase. J Clin Pathol 1984; 37: 1363-9.
40. Ghazizadeh M, et al. Immunohistochemical detection of CEA in benign hyperplasia and adenocarcinoma of the prostate with monoclonal antibody. J Urol 1984; 131: 501-4.
41. Jelbart ME, et al. Site-specific growth of the prostate xenograft line UCRU-PR-2. Prostate 1989; 14: 163-75.
42. Sim SJ, et al. Serum calcitonin in small cell carcinoma of the prostate. Ann Clin Lab Sci 1996; 26: 487-95.
43. Sloane JP, Ormerod M.G. Distribution of epithelial membrane antigen in normal and neoplastic tissues and its value in diagnostic tumor pathology. Cancer 1981; 47: 1786-95.
44. Ansari MA, et al. Diagnosis of carcinoid-line metastatic prostatic carcinoma by an immunoperoxidase method. Am J Clin Pathol 1981; 76: 94-8.
45. Ghali VS, Garcia R.L. Prostatic adenocarcinoma with carcinoidal features producing adrenocorticotropic syndrome. Cancer 1984; 54: 1043-8.
46. Almagro U.A. Argyrophilic prostatic carcinoma. Case report with literature review on prostatic carcinoid and 'carcinoid-like' prostatic carcinoma. Cancer 1985; 55: 608-14.
47. Smith C.S. Small cell carcinoma of the prostate. J Urol 1985; 133: 371A, (abstract 1029).
48. Angelsen A, et al. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 1997; 30: 1-6.
49. Wu JT, et al. Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients. J Clin Lab Anal 1998; 12: 20-5.
50. Berruti A, et al. Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. Ann Oncol 2001; 12(Suppl 2): S153-7.
51. Isshiki S, et al. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 2002; 167: 512-5.
52. Kamiya N, et al. Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. Eur Urol 2003; 44: 309-14.
53. Osterling JE, Hauzeur CG, Farrow G.M. Small cell anaplastic carcinoma of the prostate: a clinical, pathologic and immunohistochemical study of 27 patients. J Urol 1992; 147: 804-7.
54. Oshimura M, Sandberg A.A. Isochromosome 17 in prostatic cancer. J Urol 1975; 114: 249-50.
55. Atkin NB, Baker M.C. Chromosome 10 deletion in carcinoma of the prostate. N Engl J Med 1985; 312: 315.
56. Pittman S, et al. Flow cytometric and karyotypic analysis of a primary small cell carcinoma of the prostate: a xenografted cell line. Cancer Genet Cytogenet 1987; 26: 165-9.
57. Whang-Peng J, et al. A non-random chromosomal abnormality, del 3p (14-23), in human small cell lung cancer (SCCL). Cancer Genet Cytogenet 1982; 6: 119-34.
58. Wurster-Hill DH, et al. Cytogenetics of small cell carcinoma of the lung. Cancer Genet Cytogenet 1984; 13: 303-30.
59. Viola MV, et al. Expression of ras oncogene p2l in prostate cancer. N Engl J Med 1986; 314: 133-7.
60. Rijnders AWM, et al. Expression of cellular oncogenes in human prostatic carcinoma cell lines. Biochem Biophys Res Commun 1985; 132: 548-54.
61. Plummer H, et al. c-myc Expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. Cancer Res 1993; 53: 4337-42.
62. Raghavan D, et al. The interpretation of marker protein assays: a critical appraisal in clinical studies and a xenograft model. Br J Cancer 1980; 41(suppl IV): 191-4.
63. Noordzij MS, et al. Neuroendocrine differentiation in human prostatic tumor models. Am J Pathol 1991; 149: 859-71.
64. Perez-Stable C, et al. Prostate cancer progression, metastasis, and gene expression in transgenic mice. Cancer Res 1997; 57: 900-6.
65. Cohen R, et al. The neuroendocrine cell population of the human prostate gland. J Urol 1993; 150: 365-8.
66. Pearse AGE, Pollak J.M. Neural crest origin of the endocrine polypeptide (APUD) cell of the gastrointestinal cell and pancreas. Gut 1971; 12: 783-8.
67. Pearse AG, Takor T. Embryology of the diffuse neuroendocrine system and its relationship to the common peptides. Fed Proc 1979; 38: 2288-94.
68. LeDouarin N, Tellet M.A. The migration of neural crest cells to the wall of the digestive tract in the avian embryo. J Embryol ExpMorphol 1972; 30: 31-48.
69. Schron DS, Gipson T, Mendelsohn G. The histogenesis of small cell carcinoma of the pancreas: an immunohistological study. Cancer 1984; 53: 2478-80.
70. Helpap BB, Kollerman J, Ochler U. Neuroendocrine differentiation in prostatic carcinoma: histogenesis, biology, clinical relevance, and future therapeutic perspectives. Urol Int 1999; 62: 133-8.
71. Duguid JB, Kennedy A.M. Oat cell tumors of mediastinal glands. J Pathol Bacteriol 1930; 33: 93-9.
72. Brown JR, et al. Small-cell cancers, an unusual reaction to chemotherapy. J Clin Oncol 2003; 21: 2437-43.
73. Dauge MC, Delmas V. APUD type endocrine tumor of the prostate. Incidence and prognosis in association with adenocarcinoma. Prog Clin Biol Res 1987; 243A: 529.
74. Amato RJ, et al. Chemotherapy for small cell carcinoma of prostatic origin. J Urol 1992; 147: 935-7.
75. Montasser AY, Ong MG, Mehta V.T. Carcinoid tumor of the prostate associated with adenocarcinoma. Cancer 1979; 44: 307-10.
76. Wasserstein PW, Goldman R.L. Diffuse carcinoid of prostate. Urology 1981; 18: 407-9.
77. McCutcheon IE, Eng DY, Logothetis C.J. Brain metastases from prostate carcinoma. Antemortem recognition and outcome after treatment. Cancer 1999; 86: 2301-11.
78. Oesterling JE, Hauzeur CG, Farrow G.M. Small cell anaplastic carcinoma of the prostate: a clinical pathological and immunohistochemical study of 27 patients. J Urol 1992; 147: 804-7.
79. Bradley JD, et al. Positron emission tomography in limited-stage small-cell lung cancer: A prospective study. J Clin Oncol 2004; 22: 3248-54.
80. Brink I, et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004; 31: 1614-20.
81. Torii K, et al. A case of small cell carcinoma of the esophagus detected incidentally by FDG-PE.T. Ann Nucl Med 2004; 18: 699-702.
82. Chander S, et al. Small cell carcinoma of the parotid gland: evaluation with FDG PET imaging. Clin Nucl Med 2004; 29: 502-3.
83. Bishop JF, Raghavan D, Stuart-Harris R, et al. Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small cell lung cancer. J Clin Oncol 1987; 5: 1574-9.
84. Seifker-Radtke AO, et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the MD Anderson cancer experience. J Urol 2004; 172: 481-4.
85. Quek ML, et al. Radical cystectomy for primary neuroendocrine tumors of the bladder: The University of Southern California experience. J Urol 2005; 174: 93-6.
86. Murren JR, Turrisi AT, Pass H.I. Small cell lung cancer. In Devita VT Jr, Hellman S, Rosenberg SA (eds) Cancer Principles and Practice of Oncology, 7th ed. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins, 2005: 810-843.
87. Creaven PJ, et al. Paclitaxel and carboplatin in early phase studies: Roswell Park Cancer Institute experience in the subset of patients with lung cancer. Semin Oncol 1997; 24(suppl 12): 138-43.
88. Galanis E, Frytak S, Lloyd R.V. Extrapulmonary small cell carcinoma. Cancer 1997; 79: 1729-36.
89. Papandreou CN, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with small-cell carcinoma of the prostate. J Clin Oncol 2002; 20: 3072-80.
90. Brevini TA, Bianchi R, Motta M. Direct inhibitory effect of Somatostatin on the growth of the human prostate cancer cell line LNCaP: possible mechanisms of action. J Clin Endocrinol Metab 1993; 77: 626.
91. Spieth ME, Lin G, Nguyen T.T. Diagnosis and treating small-cell carcinomas of prostatic origin. Clin Nucl Med 2002; 27: 11-7.
92. Mackey JR, et al. Genitourinary small cell carcinoma: determination of clinical and therapeutic factors associated with survival. J Urol 1998; 159: 1624-9.
93. Weinstein MH, et al. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996; 27: 683-7.
94. Stirling WC, Ash J.E. Sarcoma of the prostate. J Urol 1939; 41: 515-33.
95. Schmidt JD, Welch M.J. Sarcoma of the prostate. Cancer 1976; 37: 1908-12.
96. Russo P, et al. Adult urological sarcoma. J Urol 1992; 147: 1032-6.
97. Smith BH, Dehner J.P. Sarcoma of the prostate gland. Am J Clin Pathol 1972; 58: 43-50.
98. Sexton WJ, et al. Adult prostate sarcoma: The MD Anderson cancer center experience. J Urol 2001; 166: 521-5.
99. Coindre JM, et al. Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer 1986; 58: 306-9.
100. Shiraki M, et al. Pathologic analysis of advanced adult soft tissue sarcomas, bone sarcomas, and mesotheliomas. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 1989; 64: 484-90.
101. Alvegard TA, Berg N.O. Histopathology peer review of high-grade soft tissue sarcoma: the Scandinavian Sarcoma Group experience. J Clin Oncol 1989; 7: 1845-51.
102. Fletcher CDM, et al. Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: Prognostic relevance of subclassification. J Clin Oncol 2001; 19: 3045-50.
103. Enzinger FM, Weiss S.W. General considerations. In Enzinger FM, Weiss SW (eds) Soft Tissue Sarcomas. St. Louis, Missouri: CV Mosby, 1988: 1-17.
104. Reddick RL, Michellitch H, Triche T.J. Malignant soft tissue tumors (malignant fibrous histiocytoma, pleomorphic liposarcoma, and pleomorphic rhabdomyosarcoma): an electron microscope study. Hum Pathol 1979; 10: 327-43.
105. Enzinger FM, Weiss S.W. Immunohistochemistry of soft tissue lesions. In Enzinger FM, Weiss SW (eds) Soft Tissue Sarcomas. St. Louis, Missouri: CV Mosby, 1988: 93-101.
106. Sandberg AA, Turc-Carel C, Gemmill R.M. Chromosomes in solid tumors and beyond. Cancer Res 1988; 48: 1049-59.
107. Mitelman F, Kaneko Y, Trent J.M. Report of the committee on chromosome changes in neoplasia. Cytogenet Cell Genet 1990; 55: 358-86.
108. Koufos A, et al. Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism. Nature 1985; 316: 330-4.
109. Khan J, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. NatMed 2001; 7: 673-9.
110. Nielsen TO, et al. Molecular characterization of soft tissue tumors: a gene expression study. Lancet 2002; 359: 1301-7.
111. Khan J, et al. CDNA microarrays detect activation of a myogenic transcription program by the PAC3-FKHR fusion oncogene. Proc Natl Acad Sci U S A 1999; 96: 13264-9.
112. Lessnick SL, Dacwag CS, Golub T.R. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell 2002; 1: 393-401.
113. Allander SV, et al. Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res 2001; 61: 8624-8.
114. Allander SV, et al. Expression of synovial sarcoma by cDNA microarrays: Association of ERBB2, IGHBP2, and ELF3 with epithelial differentiation. Am J Pathol 2002; 161: 1587-95.
115. Bain GO, et al. Malignant fibrous histiocytoma of prostate gland. Urology 1985; 26: 89-91.
116. Hulbert JC, Rodriguez PN, Cummings K.B. Perineal liposarcoma: diagnosis and management. J Urol 1984; 131: 1185-7.
117. Smith DM, et al. Angiosarcoma of the prostate: report of 2 cases and review of the literature. J Urol 1986; 135: 382-4.
118. Cea PC, Ward J.N. Sarcoma of the prostate 13 years after suprapubic prostatectomy. J Urol 1977; 117: 129-30.
119. Mottola A, et al. Leiomyosarcoma of the prostate. Eur Urol 1985; 11: 131-3.
120. Cheville JC, et al. Leiomyosarcoma of the prostate. Report of 23 cases. Cancer 1995; 76: 1422-7.
121. Iwasaki H, et al. Synovial sarcoma of the prostate with t(x;18) (p11.2;q11.2). Am J Surg Pathol 1999; 23: 220-6.
122. Williams D, et al. Synovial sarcoma of the prostate. J Urol 2004; 171: 2376.
123. Peterson LJ, Paulson D.F. Rhabdomyosarcoma in adult prostate. Urology 1974; 3: 689-92.
124. Dupree WB, Fisher C. Rhabdomyosarcoma of prostate in adult. Longterm survival and problem of histologic diagnosis. Urology 1982; 19: 80-2.
125. Keenan DJM, Graham W.H. Embryonal rhabdomyosarcoma of the prostatic-urethral region in an adult. Br J Urol 1985; 57: 241.
126. Palmer MA, Viswanath S, Desmond A.D. Adult prostatic rhabdomyosarcoma. Br J Urol 1993; 71: 489-90.
127. Miettinen M. Rhabdomyosarcoma in patients older than 40 years of age. Cancer 1988; 62: 2060-5.
128. Waring PM, Newland R.C. Prostatic embryonal rhabdomyosarcoma in adults. A clinicopathologic review. Cancer 1992; 69: 755-62.
129. Lopez-Beltran A, et al. Malignant phyllodes tumor of prostate. Urology 1990; 35: 164-7.
130. Manivel C, et al. Cystosarcoma phyllodes of the prostate. Arch Pathol Lab Med 1986; 110: 534-8.
131. Reese JH, et al. Phyllodes type of atypical prostatic hyperplasia: a report of 3 new cases. J Urol 1987; 138: 623-6.
132. Yokota T, et al. Malignant cystosarcoma phyllodes of prostate. Acta Pathol Jpn 1984; 34: 663-8.
133. Gueft B, Walsh M.A. Malignant prostatic cystosarcoma phyllodes. N Y State J Med 1975; 75: 2226-8.
134. Yum M, Miller JC, Agrawal B.L. Leiomyosarcoma arising in atypical fibromuscular hyperplasia (phyllodes tumor) of the prostate with distant metastasis. Cancer 1991; 68: 910-5.
135. Tetu B, et al. Atypical spindle cell lesions of the prostate. Semin Diagn Pathol 1988; 5: 284-93.
136. Gaudin PB, Rosai J, Epstein J.I. Sarcomas and related proliferative lesions of specialized prostatic stroma: A clinicopathologic study of 22 cases. Am J Surg Pathol 1998; 22: 148-62.
137. Watanabe M, et al. Malignant phyllodes tumor of the prostate: retrospective review of specimens obtained by sequential transurethral resection. Pathol Int 2002; 52: 777-83.
138. Kim HS, et al. Malignant phyllodes tumor of prostate. Pathol Int 1999; 49: 1105-8.
139. Schapmans S, et al. Phyllodes tumor of the prostate. A case report and review of the literature. Eur Urol 2000; 38: 649-53.
140. Lam KC, Yeo W. Chemotherapy induced complete remission in malignant phyllodes tumor of the prostate metastasizing to the lung. J Urol 2002; 168: 1104-5.
141. Tijare JR, Shrikhande AV, Shrikhande V.V. Phyllodes type of atypical prostatic hyperplasia. J Urol 1999; 162: 803-4.
142. Yamamoto S, et al. Malignant phyllodes tumor of the prostate. Int J Urol 2000; 7: 378-81.
143. Young JF, Jensen PE, Wiley C.A. Malignant phyllodes tumor of prostate. A case report with immunohistochemical and ultrastructural studies. Arch Pathol Lab Med 1992; 116: 296-9.
144. Bostwick DG, et al. Phyllodes tumor of the prostate: Long-term followup study of 23 cases. J Urol 2004; 172: 894-9.
145. Zenklusen HR, et al. Carcinosarcoma of the prostate in combination with adenocarcinoma of the prostate and adenocarcinoma of the seminal vesicles. A case report with immunocytochemical analysis and review of the literature. Cancer 1990; 66: 998-1001.
146. Wick MR, et al. Prostatic carcinosarcomas. Clinical, histologic, and immunohistochemical data on two cases, with a review of the literature. Am J Clin Pathol 1989; 92: 131-9.
147. Ginesin Y, et al. Carcinosarcoma of the prostate. Eur Urol 1986; 12: 441-2.
148. Krastanova LJ, Addonizio J.C. Carcinosarcoma of prostate. Urology 1981; 18: 85-8.
149. Tannenbaum M. Carcinoma with sarcomatoid changes or carcinosarcoma of prostate. Urology 1975; 6: 91-3.
150. Quay SC, Proppe K.H. Carcinosarcoma of the prostate: case report and review of the literature. J Urol 1981; 125: 436-8.
151. Martin SA, et al. Carcinosarcoma of the prostate: report of a case with ultrastructural observations. J Urol 1979; 122: 709-11.
152. Hokamura K, et al. Carcinosarcoma of the prostate. Acta Pathol Jpn 1985; 35: 481-7.
153. Lindboe CF, Mjones J. Carcinosarcoma of prostate. Immunohistochemical and ultrastructural observations. Urology 1992; 40: 376-80.
154. Nazeer T, et al. Prostatic carcinosarcoma: Case report and review of literature. J Urol 1991; 146: 1370-3.
155. Kubosawa H, et al. Carcinosarcoma of the prostate. Acta Pathol Jpn 1993; 43: 209-14.
156. Shannon RL, et al. Sarcomatoid carcinoma of the prostate. A clinicopathologic study of 12 patients. Cancer 1992; 69: 2676-82.
157. Fukawa T, et al. Prostatic carcinosarcoma: A case report and review of literature. Int J Urol 2003; 10: 108-13.
158. Dundore PA, et al. Carcinosarcoma of the prostate: Report of 21 cases. Cancer 1995; 76: 1035-42.
159. Mostofi FK, Price E.B. Malignant tumors of the prostate. Atlas of Tumor Pathology: Tumors of Male Genital System. series 2, part 8. Washington, District of Columbia: Armed Forces Institute of Pathology, 1973: 257-258.
160. Chung LW, et al. Co-inoculation of tumorigenic rat prostate mesenchymal cells with non-tumorigenic epithelial cells results in the development of carcinosarcoma in syngeneic and athymic animals. Int J Cancer 1989; 43: 1179-87.
161. Pierce SM, et al. Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys 1992; 23: 915-23.
162. Mark RJ, et al. Postirradiation sarcomas. A single-institution study and review of the literature. Cancer 1994; 73: 2653-62.
163. Amendola BE, et al. Radiation-associated sarcoma: A review of 23 patients with postradiation sarcoma over a 50-year period. Am J Clin Oncol 1989; 12: 411-5.
164. Cha C, et al. Long-term results with resection of radiation-induced soft tissue sarcomas. Ann Surg 2004; 239: 903-10.
165. Laskin WB, Silverman TA, Enzinger F.M. Postradiation soft tissue sarcomas. An analysis of 53 cases. Cancer 1988; 62: 2330-40.
166. Huvos AG, et al. Postradiation osteogenic sarcoma of bone and soft tissues. A clinicopathologic study of 66 patients. Cancer 1985; 55: 1244-55.
167. Scully JM, et al. Radiation-induced prostatic sarcoma: A case report. J Urol 19909; 144: 746-8.
168. McKenzie M, et al. Postirradiation sarcoma after external beam radiation for localized adenocarcinoma of the prostate: Report of three cases. Urology 1999; 53: 1228.
169. Prevost JB, et al. Post irradiation sarcoma after external bean radiation therapy for localized adenocarcinoma of the prostate. Tumori 2004; 90: 618-21.
170. Terris M.K. Transrectal ultrasound appearance of radiation-induced prostatic sarcoma. Prostate 1998; 37: 182-6.
171. Joerger M, et al. Postradiation high-grade myofibroblastic sarcoma of the prostate-a rare entity of prostatic tumors-responding to liposomal doxorubicin. Onkologie 2002; 25: 558-61.
172. Nishiyama T, et al. Osteogenic sarcoma of the prostate. Int J Urol 2001; 8: 199-201.
173. Canfield SE, et al. Postradiation prostatic sarcoma: de novo carcinogenesis or dedifferentiation of prostatic adenocarcinoma? Tech Urol 2001; 7: 294-5.
174. Varghese SL, Grossfeld G.D. The prostate gland: malignancies other than adenocarcinomas. Radiol Clin North Am 2000; 38: 179-202.
175. Geoffray A, et al. Ultrasonography and computed tomography for diagnosis and follow-up of pelvic rhabdomyosarcomas in children. Pediatr Radiol 1987; 17: 132-6.
176. Bahnson RR, et al. Ultrasonography and diagnosis of pediatric genitourinary rhabdomyosarcoma. Urology 1989; 33: 64-8.
177. Terris MK, et al. Transrectal ultrasound in the evaluation of rhabdomyosarcoma involving the prostate. Br J Urol 1994; 74: 341-4.
178. Tehranzadeh J, et al. Comparison of CT and MR imaging in musculoskeletal neoplasms. J Comput Assist Tomogr 1989; 13: 466-72.
179. Sundaram M, McLeod R.A. MR imaging of tumor and tumorlike lesions of bone and soft tissue. AJR Am J Roentgenol 1990; 155: 817-24.
180. Bartolozzi C, et al. Rhabdomyosarcoma of the prostate: MR findings. AJR Am J Roentgenol 1988; 150: 1333-4.
181. Kattan MW, Leung DHY, Brennan M.F. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 2002; 20: 791-6.
182. Borden EC, et al. Soft tissue sarcomas of adults: State of the translational science. Clin Cancer Res 2003; 9: 1941-56.
183. Markhede G, Angervall L, Stener B. A multivariate analysis of the prognosis after surgical treatment of malignant soft-tissue sarcomas. Cancer 1982; 49: 1721-33.
184. Tsujimoto M, et al. Multivariate analysis for histologic prognostic factors in soft tissue sarcomas. Cancer 1988; 62: 994-8.
185. Rooser B, et al. Prognostication in soft tissue sarcoma. A model with four risk factors. Cancer 1988; 61: 817-23.
186. Heslin MJ, et al. Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management. J Clin Oncol 1997; 15: 2832-9.
187. Pisters PWT, et al. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996; 14: 1679-89.
188. American Joint Committee on Cancer. Soft tissue sarcoma. In AJCC Cancer Staging Manual, 6th ed. Philadelphia, Pennsylvania, Lippincott-Raven, 2002: 221-228.
189. Levine EA, et al. Evaluation of newer prognostic markers for adult soft tissue sarcomas. J Clin Oncol 1997; 15: 3249-57.
190. Yang JC, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998; 16: 197-203.
191. Zagars GK, et al. Preoperative vs. postoperative radiation therapy for soft tissue sarcoma: a retrospective comparative evaluation of disease outcome. Int J Radiat Oncol Biol Phys 2003; 56: 482-8.
192. Potter DA, et al. Patterns of recurrence in patients with high-grade soft-tissue sarcomas. J Clin Oncol 1985; 3: 353-66.
193. Jaques DP, et al. Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum. Ann Surg 1990; 212: 51-9.
194. Glenn J, et al. Results of multimodality therapy of resectable softtissue sarcomas of the retroperitoneum. Surgery 1985; 97: 316-25.
195. Farhood AI, et al. Soft tissue sarcomas of the head and neck in adults. Am J Surg 1990; 160: 365-9.
196. Meijer S, et al. Primary colorectal sarcoma. A retrospective review and prognostic factor study of 50 consecutive patients. Arch Surg 1990; 125: 1163-8.
197. Maurer HM, et al. The intergroup rhabdomyosarcoma study-I. A final report. Cancer 1988; 61: 209-20.
198. Maurer HM, et al. The intergroup rhabdomyosarcoma study-I.I. Cancer 1993; 71: 1904-22.
199. Crist W, et al. The third intergroup rhabdomyosarcoma study. J Clin Oncol 1995; 13: 610-30.
200. Crist WM, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001; 19: 3091-102.
201. Arndt C, et al. Does bladder preservation (as a surgical principle) lead to retaining bladder function in bladder/prostate rhabdomyosarcoma? Results from Intergroup Rhabdomyosarcoma study I.V. J Urol 2004; 171: 2396-403.
202. Brennan MF, et al. Soft tissue sarcomas. In Devita VT Jr, Hellman S, Rosenberg SA (eds). Cancer Principles and Practice of Oncology, 7th edition. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins, 2005: 1581-1637.
203. Sarcoma Meta-analysis Collaboration (SMAC). Adjuvant chemotherapy for localized respectable soft tissue sarcoma in adults. Cochrane Database Syst Rev 2000; 2: CD001419.
204. Frustaci S, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001; 19: 1238-47.
205. Petrioli R, et al. Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma. Am J Clin Oncol 2002; 25: 468-73.
206. Glenn J, et al. A randomized, prospective trial of adjuvant chemotherapy in adults with soft tissue sarcomas of the head and neck, breast, and trunk. Cancer 1985; 55: 1206-14.
207. Parkin DM, Bray F, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
208. Melicow MM, Hollowell J.W. Intra-urothelial cancer: carcinoma in situ, Bowen's disease of the urinary system: discussion of thirty cases. J Urol 1952; 68: 763-72.
209. Kahler J.E. Carcinoma of the prostate gland: a pathologic study. J Urol 1939; 41: 557.
210. Thompson G.J. Transurethral resection of malignant lesions of the prostate gland. JAMA 1942; 120: 1105.
211. Ortega LG, Whitmore WF, Murphy A.I. In situ carcinoma of the prostate with intraepithelial extension into the urethra and bladder. Cancer 1953; 6: 898.
212. Salazar G, Frable W.J. Extramammary Paget's disease: a case involving the prostatic urethra. Am J Clin Pathol 1969; 52: 607-12.
213. Chesterman FC, Franks L.M. Intra-epithelial carcinoma of prostatic urethra, peri-urethral glands, and prostatic ducts (Bowen's disease of urinary epithelium). Br J Cancer 1956; 10: 223-5.
214. Ende N, Woods LP, Shelley H.S. Carcinoma originating in ducts surrounding the prostatic urethra. Am J Clin Pathol 1963; 40: 183-9.
215. Karpas CM, Moumgis B. Primary transitional cell carcinoma of prostate gland: possible pathogenesis and relationship to reserve cell hyperplasia of prostatic periurethral ducts. J Urol 1969; 101: 201-5.
216. Bates H.R. Transitional cell carcinoma of the prostate. J Urol 1969; 101: 206-7.
217. Johnson DE, Hogan JM, Ayala A.G. Transitional cell carcinoma of the prostate. A clinical morphological study. Cancer 1972; 29: 287-93.
218. Seemayer TA, et al. Further observations on carcinoma in situ of the urinary bladder: silent but extensive intraprostatic involvement. Cancer 1975; 36: 514-20.
219. Grabstald H. Prostatic biopsy in selected patients with carcinoma in situ of the bladder: preliminary report. J Urol 1984; 132: 1117-8.
220. Rhamy RK, Buchanan RD, Spalding M.J. Intraductal carcinoma of the prostate gland. J Urol 1973; 109: 457-60.
221. Montie JE, et al. The significance and management of transitional cell carcinoma of the prostate. Semin Urol 1990; 8: 262-8.
222. Rubenstein AB, Rubnitz M.E. Transitional cell carcinoma of the prostate. Cancer 1969; 24: 543-6.
223. Montie JE, Mirsky H, Levin H. Transitional cell carcinoma of the prostate in a series of cystectomies: incidence and staging problems. J Urol 1986; 135: 243A, (abstract 557).
224. Matzkin H, Soloway MS, Hardeman S. Transitional cell carcinoma of the prostate. J Urol 1991; 146: 1207-12.
225. Albert PS, Mallouh C, Nagamatsu G.R. Transitional-cell carcinoma of prostate: an enigma. Urology 1973; 2: 128-30.
226. Goebbels R, et al. Urothelial carcinoma of the prostate. Appl Pathol 1985; 3: 242-54.
227. Zincke H, Utz DC, Farrow G.M. Review of the Mayo clinic experience with carcinoma in situ. Urology 1985; 26(4 Suppl): 39-46.
228. Tannenbaum M. Transitional cell carcinoma of prostate. Urology 1975; 5: 674-8.
229. Dhom G, Mohr G. Urothel-Carcinome in der Prostata. Urologe A 1977; 16: 70-2.
230. Pagano F, et al. Is stage pT4a (D1) reliable in assessing transitional cell carcinoma involvement of the prostate in patients with a concurrent bladder cancer? A necessary distinction for contiguous or noncontiguous involvement. J Urol 1996; 155: 244-7.
231. Schellhammer PF, Bean MA, Whitmore W.F. Prostatic involvement by transitional cell carcinoma: pathogenesis, patterns and prognosis. J Urol 1977; 118: 399-403.
232. Wood DP, et al. Transitional cell carcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. J Urol 1989; 141: 346-9.
233. Honda N, et al. Clinical study of transitional cell carcinoma of the prostate associated with bladder transitional cell carcinoma. Int J Urol 2001; 8: 662-8.
234. Esrig D, et al. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion. J Urol 1996; 156: 1071-6.
235. Kirk D, et al. Transitional cell carcinoma involving the prostate-an unfavorable prognostic sign in the management of bladder cancer?. Br J Urol 1981; 53: 610.
236. Hudson MA, Catalona W.J. Urothelial tumors of the bladder, upper tracts, and prostate. In Gillenwater JY et al. (eds) Adult and Pediatric Urology. St Louis, Missouri: Mosby-Year Book, 1996.
237. Mevorach RA, et al. Human papillomavirus type 6 in grade I transitional cell carcinoma of the urethra. J Urol 1990; 143: 126.
238. Monseur J, et al. Asbestose du col vésical et de la prostate. J Urol 1986; 92: 17.
239. Ullmann AS, Ross O.A. Hyperplasia, atypism, and carcinoma in situ in prostatic periurethral glands. Am J Clin Pathol 1967; 47: 497.
240. Mahadevia PS, Koss LG, Tar I.J. Prostatic involvement in bladder cancer: prostate mapping in 20 cystoprostatectomy specimens. Cancer 1986; 58: 2096.
241. Montie JE, et al. Transitional cell carcinoma in situ of the seminal vesicles: 8 cases with discussion of pathogenesis, and clinical and biological implications. J Urol 1997; 158: 1895.
242. Dube VE, Farrow GM, Greene L.F. Prostatic adenocarcinoma of ductal origin. Cancer 1973; 32: 402.
243. Aydin F. Endometrioid adenocarcinoma of prostatic urethra presenting with anterior urethral implantation. Urology 1993; 41: 91.
244. Bostwick D.G. Neoplasms of the prostate. In Bostwick DG, Eble J.N. (eds) Urologic Surgical Pathology. St. Louis, Missouri: Mosby-Year Book, 1997.
245. Sawczuk I, et al. Primary transitional cell carcinoma of prostatic periurethral ducts. Urology 1985; 25: 339.
246. Greene LF, O'Dea MJ, Dockerty M.B. Primary transitional cell carcinoma of the prostate. J Urol 1976; 116: 761.
247. Murphy WM, Gaeta J.F. Diseases of the prostate gland and seminal vesicals. In Murphy WM (ed) Urological Pathology. Philadelphia, Pennsylvania: WB Saunders, 1989.
248. Bryan RL, et al. The significance of prostatic urothelial dysplasia. Histopathology 1993; 22: 501.
249. Wishnow KI, Ro J.Y. Importance of early treatment of transitional cell carcinoma of prostatic ducts. Urology 1988; 32: 11.
250. Prout GR, et al. Carcinoma in situ of the urinary bladder with and without associated vesical neoplasms. Cancer 1983; 52: 524.
251. Cheville JC, et al. Transitional cell carcinoma of the prostate: clinicopathologic study of 50 cases. Cancer 1998; 82: 703.
252. Freeman JA, et al. Management of the patient with bladder cancer: urethral recurrence. Urol Clin North Am 1994; 21: 645.
253. Freeman JA, et al. Urethral recurrence in patients with orthotopic ileal neobladders. J Urol 1996; 156: 1615.
254. Algaba F, et al. Transitional cell carcinoma of the prostate. Eur Urol 1985; 11: 87-90.
255. Winfield HN, Reddy PK, Lange P.H. Coexisting adenocarcinoma of prostate in patients undergoing cystoprostatectomy for bladder cancer. Urology 1987; 30: 100.
256. Pritchett TR, et al. Unsuspected prostatic adenocarcinoma in patients who have undergone radical cystoprostatectomy for transitional cell carcinoma of the bladder. J Urol 1988; 139: 1214.
257. Dhom G. Histopathology of prostate carcinoma: diagnosis and differential diagnosis. Pathol Res Pract 1985; 179: 277.
258. Marshall V.F. The relation of the preoperative estimate to the pathologic demonstration of the extent of vesical neoplasms. J Urol 1952; 68: 714.
259. Samsonov VA, Kolomoitsev S.V. Dimorphic (transitional-anaplastic) ductal cancer of the prostate. Arkh Patol 1984; 46: 71.
260. Lemberger RJ, et al. Carcinoma of the prostate of ductal origin. Br J Urol 1984; 56: 706.
261. Zincke H, Utz DC, Farrow G.M. Review of the Mayo clinic experience with carcinoma in situ. Urology 1985; 26: 39.
262. Nicolaisen GS, Williams R.D. Primary transitional cell carcinoma of the prostate. Urology 1984; 24: 544.
263. Wolfe JHN, Lloyd-Davies R.W. The management of transitional cell carcinoma of the prostate. Br J Urol 1981; 53: 253.
264. Razvi M, Firfer R, Berkson B. Occult transitional cell carcinoma of the prostate presenting as skin metastasis. J Urol 1975; 113: 734.
265. Wendelken JR, et al. Transitional cell carcinoma: cause of refractory cancer of the prostate. Urology 1979; 13: 557.
266. Epstein N.A. The cytologic appearance of metastatic transitional cell carcinoma. Acta Cytol 1977; 21: 723.
267. Griffiths GJ, et al. The ultrasound appearances of prostatic cancer with histological correlation. Clin Radiol 1987; 38: 219.
268. Terris MK, Villers A, Freiha F.S. Transrectal ultrasound appearance of transitional cell carcinoma involving the prostate. J Urol 1990; 143: 953.
269. Beer M, Schmidt H, Riedl R. Klinische Wertigkeit des präoperativen Stagings von Blasen-und Prostatakarzinomen mit NMR und Computertomographie. Urologe A 1989; 28: 65.
270. Wood DP, et al. Identification of transitional cell carcinoma of the prostate in bladder cancer patients: a prospective study. J Urol 1989; 141: 83-5.
271. Bates HR, Thornton J.L. Carcinoma of prostatic ducts. Am J Clin Pathol 1966; 45: 96.
272. Laplante M, Brice M. The upper limits of hopeful application of radical cystectomy for vesical carcinoma: does nodal metastasis always indicate incurability? J Urol 1973; 109: 261.
273. Thelmo WL, et al. Carcinoma in situ of the bladder with associated prostatic involvement. J Urol 1974; 111: 491.
274. Greene LF, et al. Primary transitional cell carcinoma of the prostate. J Urol 1973; 110: 235.
275. Rikken CHM, Van Helsdingen PJRO, Kazzaz B.A. Are biopsies from the prostatic urethra useful in patients with superficial bladder carcinoma. Br J Urol 1987; 59: 145.
276. Sakamoto N, et al. An adequate sampling of the prostate to identify prostatic involvement by urothelial carcinoma in bladder cancer patients. J Urol 1993; 149: 318.
277. Laor E, Grabstald H, Whitmore W.F. The influence of simultaneous resection of bladder tumors and prostate on the occurrence of prostatic urethral tumors. J Urol 1981; 126: 171.
278. Chibber PJ, et al. Transitional cell carcinoma involving the prostate. Br J Urol 1981; 53: 605-9.
279. Kirk D, Hinton CE, Shaldon C. Transitional cell carcinoma of the prostate. Br J Urol 1979; 51: 575-8.
280. Raz S, et al. Management of the urethra in patients undergoing radical cystectomy for bladder carcinoma. J Urol 1978; 120: 298.
281. Solsona E, et al. The prostate involvement as prognostic factor in patients with superficial bladder tumors. J Urol 1995; 154: 1710.
282. Reese JH, et al. Transitional cell carcinoma of the prostate in patients undergoing radical cystoprostatectomy. J Urol 1992; 147: 92.
283. Palou J, et al. In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guerin therapy without previous transurethral resection of the prostate. Urology 1996; 47: 482.
284. Bretton PR, et al. Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra. J Urol 1989; 141: 853.
285. Hillyard RW, Ladaga L, Schellhammer P.F. Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical bacillus Calmette-Guerin. J Urol 1988; 139: 290.
286. Orihuela E, Herr HW, Whitmore W.F. Conservative treatment of superficial transitional cell carcinoma of prostatic urethra with intravesical B.C.G. Urology 1989; 34: 231.
287. Schellhammer PF, Ladaga LE, Moriarty R.P. Intravesical bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the prostatic urethra in association with carcinoma of the bladder. J Urol 1995; 153: 53.
288. Lamm D. Re: Transitional cell carcinoma of the prostate, editorial. J Urol 1991; 146: 1630.
289. Droller M.J. Bacillus Calmette-Guerin in the management of bladder cancer. J Urol 1986; 135: 331.
290. Siami P, et al. BCG in management of transitional cell carcinoma invasive to prostate. Urology 1989; 34: 381.
291. Lockhart JL, et al. Prostatic recurrences in the management of superficial bladder tumors. J Urol 1983; 130: 256.
292. Droller MJ, Walsh P.C. Intensive intravesical chemotherapy in the treatment of flat carcinoma in situ: is it safe? J Urol 1985; 134: 1115.
293. Shenasky JH, Gillenwater J.Y. Management of transitional cell carcinoma of the prostate. J Urol 1972; 108: 462.
294. Kopelson G, et al. Periurethral prostatic duct carcinoma: clinical features and treatment results. Cancer 1978; 42: 2894.
295. Frazier HA, et al. The value of pathologic factors in predicting cancerspecific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 1993; 71: 3993.
296. Taylor HG, Blom J. Transitional cell carcinoma of the prostate: response to treatment with adriamycin and cis-platinum. Cancer 1983; 51: 1800.
297. Alexander SJ, Lee SS, Bekhrad A. Transitional cell carcinoma of the prostate: response to treatment with cisplatinum and cyclophosphamide. J Urol 1984; 131: 975.
298. Dexeus FH, et al. Complete responses in metastatic transitional cell carcinoma of the prostate with cisplatin regimens. J Urol 1987; 137: 122.
299. Takashi M, et al. Primary transitional cell carcinoma of prostate: case with lymph node metastasis eradicated by neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) therapy. Urology 1990; 36: 96.
300. von der Maase H, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-77.
301. Bajorin DF, et al. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: A phase II trial. J Clin Oncol 1998; 16: 2722-7.
302. Hussain M, et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001; 19: 2527-33.
303. Jacobi M, Panoff CE, Herzlich J. Leukemic infiltration of the prostate. J Urol 1937; 38: 494-9.
304. Johnson MA, Gundersen A. Infiltration of the prostate bland by chronic lymphatic leukemia. J Urol 1953; 69: 681-5.
305. Tighe J.R. Leukaemic infiltration of the prostate. Br J Surg 1960; 47: 658-60.
306. Vinnicombe J. Leukaemic infiltration of the prostate. Br J Urol 1963; 35: 297-8.
307. Waddington R.T. Leukaemic infiltration of the prostate in a patient with chronic lymphatic leukaemia-a case report. Br J Urol 1973; 45: 184-6.
308. Dajani YF, Burke M. Leukemic infiltration of the prostate: A case study and clinicopathological review. Cancer 1976; 38: 2442-6.
309. Butler MR, O'Flynn J.D. Prostatic disease in the leukaemic patient-with particular reference to leukaemic infiltration of the prostate-a retrospective clinical study. Br J Urol 1973; 45: 179-83.
310. Thalhammer F, et al. Granulocytic sarcoma of the prostate as the first manifestation of a late relapse of acute myelogenous leukaemia. Ann Hematol 1994; 68: 97-9.
311. Bostwick DG, et al. Malignant lymphoma involving the prostate: Report of 62 cases. Cancer 1998; 83: 732-8.
312. Weimar G, et al. Urogenital involvement by malignant lymphomas. J Urol 1980; 125: 230-1.
313. Zein TA, et al. Secondary tumors of the prostate. J Urol 1985; 133: 615-6.
314. Freeman C, Berg JW, Cutler S.J. Occurrence and prognosis of extranodal lymphomas. Cancer 1972; 29: 252-60.
315. Rosenberg SA, et al. Lymphosarcoma: A review of 1269 cases. Medicine 1961; 40: 31-84.
316. Sarris A, et al. Primary lymphoma of the prostate: good outcome with doxorubicin-based combination chemotherapy. J Urol 1995; 153: 1852-4.
317. Klotz LH, Herr H.W. Hodgkin's disease of the prostate: A detailed case report. J Urol 1986; 135: 1261-2.
318. Coupland S. Lymphoma of the prostate. Trans Pathol Soc Lond 1877; 28: 179.
319. Bostwick DG, Mann R.B. Malignant lymphomas involving the prostate. Cancer 1985; 56: 2932-8.
320. King LS, Cox T.R. Lymphosarcoma of the prostate. Am J Pathol 1951; 27: 801-23.
321. Fell P, O'Connor M, Smith J.M. Primary lymphoma of prostate presenting as bladder outflow obstruction. Urology 1987; 29: 555-6.
322. Patel DR, et al. Primary prostatic involvement in non-Hodgkin lymphoma. Urology 1988; 32: 96-8.
323. Kerbl K, Pauer W. Primary non-Hodgkin lymphoma of prostate. Urology 1988; 32: 347-9.
324. Suzuki H, et al. Malignant lymphoma of the prostate. Report of a case. Urol Int 1991; 47: 172-5.
325. Sarlis NJ, et al. Primary non-Hodgkin lymphoma of the prostate gland. Int Urol Nephrol 1993; 25: 163-8.
326. Morozumi M, et al. Primary non-Hodgkin lymphoma of the prostate: a case report. Nippon Hinyokika Gakkai Zasshi 1993; 84: 2023-63.
327. Mounedji-Boudiaf L, et al. Primary, highly malignant B-cell lymphoma of the prostate. Apropos of a case and review of the literature. Bull Cancer 1994; 81: 334-7.
328. Braslis KG, et al. Primary prostatic lymphoma: a rare prostatic malignancy. Aust N Z J Surg 1994; 64: 58-9.
329. Parks RW, et al. Primary non-Hodgkin's lymphoma of the prostate mimicking acute prostatitis. Br J Urol 1995; 76: 409.
330. Ghose A, et al. Lymphoma of the prostate treated with radiotherapy. Clin Oncol (R Coll Radiol) 1995; 7: 134.
331. Bell CR, et al. Primary non-Hodgkin's lymphoma of the prostate gland: case report and review of the literature. Clin Oncol (R Coll Radiol) 1995; 7: 409-10.
332. Rainwater LM, Barrett D.M. Primary lymphoma of the prostate: Transrectal ultrasonic appearance. Urology 1990; 36: 522-5.
333. Horning SJ, Rosenberg S.A. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311: 1471-5.